News

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground.

LOGIPIX, a global leader in high-resolution intelligent computer vision solutions, was chosen after a rigorous selection process for its advanced capabilities and track record of successful implementations in high-volume commercial airside environments, such as LaGuardia Airport.

The Virtual Ramp Control System will leverage LOGIPIX’ innovative multi-sensor panoramic video technology and Airside Augmented Reality Solution (LAARS) software to provide monitoring and analysis of ground activities with live object classification and tracking, supporting the Terminal 6 gate operations center. Integrating high-resolution cameras, intelligent AI analytics, and advanced control features, the system will enhance the efficiency of aircraft management with real time decision-making support and improved situational awareness.

“We are thrilled to work with JFK Millennium Partners to deploy our Virtual Ramp Control System,” said Mike Broggie, President of LOGIPIX US Corporation. “This collaboration underscores our commitment to provide cutting-edge solutions that address the evolving needs of modern airports, and we are confident that our technology will contribute to JFK’s innovative transformation into a world-class facility.”

Implementation of the Virtual Ramp Control System will occur in two phases during construction of Terminal 6.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin